Samsung Biologics completes acquisition of Rockville biologics facility in U.S.

Rockville biologics facility.(Source=Samsung Biologics)

[Song Young Doo, Edaily Reporter] Samsung Biologics said Wednesday that it has completed the acquisition of a biologics manufacturing facility in Rockville, Maryland, from GlaxoSmithKline as of March 31(local time), marking its first production foothold in the United States.

The company finalized the deal after approximately three months of post-signing procedures following the initial agreement announced in December 2025. The acquisition was carried out through its U.S. subsidiary, Samsung Biologics America.

The Rockville facility is a drug substance(DS) manufacturing plant with a total capacity of 60,000 liters, consisting of two manufacturing buildings. It is equipped to support antibody production across a wide range of scales, from clinical development to commercial manufacturing.

With this acquisition, Samsung Biologics increased its total production capacity from 785,000 liters to 845,000 liters. The company said the new U.S. site strengthens its ability to serve clients in North America and enables a dual-site manufacturing system linking Songdo, Korea, and Rockville, providing more flexible and reliable production options for global customers.

Samsung Biologics also retained approximately 500 local employees, ensuring operational continuity. The company plans to accelerate new order intake while maintaining stable supply of existing products through integration between its two production sites. It is also reviewing additional investments to expand capacity and upgrade technologies at the Rockville facility in line with mid- to long-term demand.

“This acquisition represents a meaningful step forward in expanding our global manufacturing footprint,” said John Rim, CEO of Samsung Biologics. “We will maintain operational continuity with the experienced workforce at the Rockville site and continue to ensure a stable supply system.”